Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
American Journal of Cardiovascular Drugs
Published in: American Journal of Cardiovascular Drugs 6/2014

01-12-2014 | Review Article

The Cardioprotection of the Insulin-Mediated PI3K/Akt/mTOR Signaling Pathway

Authors: Hong Yao, Xiangyang Han, Xiuzhen Han

Published in: American Journal of Cardiovascular Drugs | Issue 6/2014

Login to get access

Abstract

Apoptosis occurs frequently in myocardial infarction, oxidative stress injury, and ischemia/reperfusion injury, and plays a pivotal role in the development of heart diseases. Inhibition of apoptosis alone does not necessarily lead to meaningful rescue in terms of either cardiomyocyte survival or function. Activation of the PI3K/Akt signaling pathway induced by insulin not only inhibits cardiomyocyte apoptosis but also substantially preserves and even improves regional and overall cardiac function. Insulin can protect cardiomyocytes from apoptosis by regulating a number of signaling molecules, such as eNOS, FOXOs, Bad, GSK-3β, mTOR, NDRG2, and Nrf2, through activating PI3K and Akt. This review focuses on the protective mechanisms and targets of insulin identified in the prevention and treatment of myocardial injury.
Literature
1.
Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, Ogawa W, del Monte F, Gwathmey JK, Grazette L, Hemmings BA, Kass DA, Champion HC, Rosenzweig A. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest. 2005;115:2128–38.PubMedCentralPubMedCrossRef
2.
Yaoita H, Ogawa K, Maehara K, Maruyama Y. Apoptosis in relevant clinical situations: contribution of apoptosis in myocardial infarction. Cardiovasc Res. 2000;45:630–41.PubMedCrossRef
3.
Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013;381:166–75.PubMedCrossRef
4.
Weeks KL, Gao X, Du XJ, Boey EJ, Matsumoto A, Bernardo BC, Kiriazis H, Cemerlang N, Tan JW, Tham YK, Franke TF, Qian H, Bogoyevitch MA, Woodcock EA, Febbraio MA, Gregorevic P, McMullen JR. Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail. 2012;5:523–34.PubMedCrossRef
5.
Ng KW, Allen ML, Desai A, Macrae D, Pathan N. Cardioprotective effects of insulin: how intensive insulin therapy may benefit cardiac surgery patients. Circulation. 2012;125:721–8.PubMedCrossRef
6.
Iliadis F, Kadoglou N, Didangelos T. Insulin and the heart. Diabetes Res Clin Pract. 2011;93(Suppl 1):S86–91.PubMedCrossRef
7.
Fu F, Ji L, Liu W, Yang W, Wang J, Zhang H, Gao F. Experimental research: early but not late insulin treatment improves left ventricular remodelling and cardiac function induced by myocardial infarction in rats. Heart. 2011;97(Suppl 3):A8.
8.
Laustsen PG, Russell SJ, Cui L, Entingh-Pearsall A, Holzenberger M, Liao R, Kahn CR. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol. 2007;27:1649–64.PubMedCentralPubMedCrossRef
9.
Kaplan M, Aviram M, Hayek T. Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy. Pharmacol Ther. 2012;136:175–85.PubMedCrossRef
10.
Morisco C, Condorelli G, Trimarco V, Bellis A, Marrone C, Condorelli G, Sadoshima J, Trimarco B. Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res. 2005;96:180–8.PubMedCrossRef
11.
Wang M, Sun GB, Sun X, Wang HW, Meng XB, Qin M, Sun J, Luo Y, Sun XB. Cardioprotective effect of salvianolic acid B against arsenic trioxide-induced injury in cardiac H9c2 cells via the PI3K/Akt signal pathway. Toxicol Lett. 2013;216:100–7.PubMedCrossRef
12.
Aikawa R, Nawano M, Gu Y, Katagiri H, Asano T, Zhu W, Nagai R, Komuro I. Insulin prevents cardiomyocytes from oxidative stress-induced apoptosis through activation of PI3 kinase/Akt. Circulation. 2000;102:2873–9.PubMedCrossRef
13.
Si R, Tao L, Zhang HF, Yu QJ, Zhang R, Lv AL, Zhou N, Cao F, Guo WY, Ren J, Wang HC, Gao F. Survivin: a novel player in insulin cardioprotection against myocardial ischemia/reperfusion injury. J Mol Cell Cardiol. 2011;50:16–24.PubMedCrossRef
14.
Harney JA, Rodgers RL. Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: involvement of PI3K but not cAMP. Am J Physiol Endocrinol Metab. 2008;295:E155–61.PubMedCentralPubMedCrossRef
15.
16.
Mehrhof FB, Müller FU, Bergmann MW, Li P, Wang Y, Schmitz W, Dietz R, von Harsdorf R. In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation. 2001;104:2088–94.PubMedCrossRef
17.
Hu X, Xu C, Zhou X, Cui B, Lu Z, Jiang H. PI3K/Akt signaling pathway involved in cardioprotection of preconditioning with high mobility group box 1 protein during myocardial ischemia and reperfusion. Int J Cardiol. 2011;150:222–3.PubMedCrossRef
18.
Ha T, Hua F, Liu X, Ma J, McMullen JR, Shioi T, Izumo S, Kelley J, Gao X, Browder W, Williams DL, Kao RL, Li C. Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc Res. 2008;78:546–53.PubMedCrossRef
19.
Cao Z, Ren D, Ha T, Liu L, Wang X, Kalbfleisch J, Gao X, Kao R, Williams D, Li C. CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion injury: involving activation of PI3K/Akt signaling. Biochim Biophys Acta. 2013;1832:96–104.PubMedCentralPubMedCrossRef
20.
Oudit GY, Penninger JM. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res. 2009;82:250–60.PubMedCrossRef
21.
McMullen JR, Shioi T, Huang WY, Zhang L, Tarnavski O, Bisping E, Schinke M, Kong S, Sherwood MC, Brown J, Riggi L, Kang PM, Izumo S. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase (p110alpha) pathway. J Biol Chem. 2004;279:4782–93.PubMedCrossRef
22.
Waardenberg AJ, Bernardo BC, Ng DC, Shepherd PR, Cemerlang N, Sbroggiò M, Wells CA, Dalrymple BP, Brancaccio M, Lin RC, McMullen JR. Phosphoinositide 3-kinase (PI3K(p110alpha)) directly regulates key components of the Z-disc and cardiac structure. J Biol Chem. 2011;286:30837–46.PubMedCentralPubMedCrossRef
23.
Shiojima I, Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev. 2006;20:3347–65.PubMedCrossRef
24.
Vadlakonda L, Dash A, Pasupuleti M, Anil Kumar K, Reddanna P. The paradox of Akt-mTOR interactions. Front Oncol. 2013;3:165.PubMedCentralPubMed
25.
Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT–a major therapeutic target. Biochim Biophys Acta. 2004;1697:3–16.PubMedCrossRef
26.
Latronico MV, Costinean S, Lavitrano ML, Peschle C, Condorelli G. Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci. 2004;1015:250–60.PubMedCrossRef
27.
Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal. 2011;23:1515–27.PubMedCrossRef
28.
DeBosch B, Sambandam N, Weinheimer C, Courtois M, Muslin AJ. Akt2 regulates cardiac metabolism and cardiomyocyte survival. J Biol Chem. 2006;281:32841–51.PubMedCentralPubMedCrossRef
29.
Fernández-Hernando C, Ackah E, Yu J, Suárez Y, Murata T, Iwakiri Y, Prendergast J, Miao RQ, Birnbaum MJ, Sessa WC. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab. 2007;6:446–57.PubMedCentralPubMedCrossRef
30.
Matsui T, Rosenzweig A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI3-kinase and Akt. J Mol Cell Cardiol. 2005;38:63–71.PubMedCrossRef
31.
Bononi A, Agnoletto C, De Marchi E, Marchi S, Patergnani S, Bonora M, Giorgi C, Missiroli S, Poletti F, Rimessi A, Pinton P. Protein kinases and phosphatases in the control of cell fate. Enzyme Res. 2011;2011:329098.PubMedCentralPubMedCrossRef
32.
Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905–27.PubMedCrossRef
33.
Théberge JF, Mehdi MZ, Pandey SK, Srivastava AK. Prolongation of insulin-induced activation of mitogen-activated protein kinases ERK1/2 and phosphatidylinositol 3-kinase by vanadyl sulfate, a protein tyrosine phosphatase inhibitor. Arch Biochem Biophys. 2003;420:9–17.PubMedCrossRef
34.
Pulakat L, Demarco VG, Whaley-Connell A, Sowers JR. The impact of overnutrition on insulin metabolic signaling in the heart and the kidney. Cardiorenal Med. 2011;1:102–12.PubMedCentralPubMedCrossRef
35.
Tong H, Rockman HA, Koch WJ, Steenbergen C, Murphy E. G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. Circ Res. 2004;94:1133–41.PubMedCrossRef
36.
Vigneron F, Dos Santos P, Lemoine S, Bonnet M, Tariosse L, Couffinhal T, Duplaà C, Jaspard-Vinassa B. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovasc Res. 2011;90:49–56.PubMedCrossRef
37.
Siddall HK, Warrell CE, Yellon DM, Mocanu MM. Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency. Basic Res Cardiol. 2008;103:560–8.PubMedCrossRef
38.
Warfel NA, Niederst M, Stevens MW, Brennan PM, Frame MC, Newton AC. Mislocalization of the E3 ligase, β-transducin repeat-containing protein 1 (β-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. J Biol Chem. 2011;286:19777–88.PubMedCentralPubMedCrossRef
39.
Krolikowski JG, Weihrauch D, Bienengraeber M, Kersten JR, Warltier DC, Pagel PS. Role of Erk1/2, p70s6K, and eNOS in isoflurane-induced cardioprotection during early reperfusion in vivo. Can J Anaesth. 2006;53:174–82.PubMedCrossRef
40.
Sun Z, Tong G, Ma N, Li J, Li X, Li S, Zhou J, Xiong L, Cao F, Yao L, Wang H, Shen L. NDRG2: a newly identified mediator of insulin cardioprotection against myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2013;108:341.PubMedCrossRef
41.
Ji L, Fu F, Zhang L, Liu W, Cai X, Zhang L, Zheng Q, Zhang H, Gao F. Insulin attenuates myocardial ischemia/reperfusion injury via reducing oxidative/nitrative stress. Am J Physiol Endocrinol Metab. 2010;298:E871–80.PubMedCrossRef
42.
Teshima Y, Takahashi N, Thuc LC, Nishio S, Nagano-Torigoe Y, Miyazaki H, Ezaki K, Yufu K, Hara M, Nakagawa M, Saikawa T. High-glucose condition reduces cardioprotective effects of insulin against mechanical stress-induced cell injury. Life Sci. 2010;87:154–61.PubMedCrossRef
43.
Tan Y, Ichikawa T, Li J, Si Q, Yang H, Chen X, Goldblatt CS, Meyer CJ, Li X, Cai L, Cui T. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes. 2011;60:625–33.PubMedCentralPubMedCrossRef
44.
Aoyagi T, Kusakari Y, Xiao CY, Inouye BT, Takahashi M, Scherrer-Crosbie M, Rosenzweig A, Hara K, Matsui T. Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2012;303:H75–85.PubMedCentralPubMedCrossRef
45.
Fuglesteg BN, Tiron C, Jonassen AK, Mjøs OD, Ytrehus K. Pretreatment with insulin before ischaemia reduces infarct size in Langendorff-perfused rat hearts. Acta Physiol (Oxf). 2009;195:273–82.CrossRef
46.
Troncoso R, Vicencio JM, Parra V, Nemchenko A, Kawashima Y, Del Campo A, Toro B, Battiprolu PK, Aranguiz P, Chiong M, Yakar S, Gillette TG, Hill JA, Abel ED, Leroith D, Lavandero S. Energy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy. Cardiovasc Res. 2012;93:320–9.PubMedCentralPubMedCrossRef
47.
Liao LZ, Chen YL, Lu LH, Zhao YH, Guo HL, Wu WK. Polysaccharide from Fuzi likely protects against starvation-induced cytotoxicity in H9c2 cells by increasing autophagy through activation of the AMPK/mTOR pathway. Am J Chin Med. 2013;41:353–67.PubMedCrossRef
48.
Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H-ATPase. Science. 2011;334:678–83.PubMedCentralPubMedCrossRef
49.
Zhai P, Sciarretta S, Galeotti J, Volpe M, Sadoshima J. Differential roles of GSK-3β during myocardial ischemia and ischemia/reperfusion. Circ Res. 2011;109:502–11.PubMedCentralPubMedCrossRef
50.
51.
Shen WH, Chen Z, Shi S, Chen H, Zhu W, Penner A, Bu G, Li W, Boyle DW, Rubart M, Field LJ, Abraham R, Liechty EA, Shou W. Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function. J Biol Chem. 2008;283:13842–9.PubMedCentralPubMedCrossRef
52.
Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294:1942–5.PubMedCrossRef
53.
Gurusamy N, Lekli I, Mukherjee S, Ray D, Ahsan MK, Gherghiceanu M, Popescu LM, Das DK. Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res. 2010;86:103–12.PubMedCentralPubMedCrossRef
54.
Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24.PubMedCrossRef
55.
Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature. 2005;433:477–80.PubMedCrossRef
56.
Mohan ML, Jha BK, Gupta MK, Vasudevan NT, Martelli EE, Mosinski JD. Naga Prasad SV. Phosphoinositide 3-kinase γ inhibits cardiac GSK-3 independently of Akt. Sci Signal. 2013;6:ra4.PubMedCentralPubMedCrossRef
57.
Shioda N, Han F, Moriguchi S, Fukunaga K. Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. J Neurochem. 2007;102:1506–17.PubMedCrossRef
58.
59.
Shioda N, Ishigami T, Han F, Moriguchi S, Shibuya M, Iwabuchi Y, Fukunaga K. Activation of phosphatidylinositol 3-kinase/protein kinase B pathway by a vanadyl compound mediates its neuroprotective effect in mouse brain ischemia. Neuroscience. 2007;148:221–9.PubMedCrossRef
60.
Ni YG, Wang N, Cao DJ, Sachan N, Morris DJ, Gerard RD, Kuro-O M, Rothermel BA, Hill JA. FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci USA. 2007;104:20517–22.PubMedCentralPubMedCrossRef
61.
Cui XB, Wang C, Li L, Fan D, Zhou Y, Wu D, Cui QH, Fu FY, Wu LL. Insulin decreases myocardial adiponectin receptor 1 expression via PI3 K/Akt and FoxO1 pathway. Cardiovasc Res. 2012;93:69–78.PubMedCrossRef
62.
Niizuma S, Inuzuka Y, Okuda J, Kato T, Kawashima T, Tamaki Y, Iwanaga Y, Yoshida Y, Kosugi R, Watanabe-Maeda K, Machida Y, Tsuji S, Aburatani H, Izumi T, Kita T, Kimura T, Shioi T. Effect of persistent activation of phosphoinositide 3-kinase on heart. Life Sci. 2012;90:619–28.PubMedCrossRef
63.
Wu CH, Liu JY, Wu JP, Hsieh YH, Liu CJ, Hwang JM, Lee SD, Chen LM, Chang MH, Kuo WW, Shyu JC, Tsai JH, Huang CY. 17beta-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats. Life Sci. 2005;78:347–56.PubMedCrossRef
64.
van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res. 2005;67:21–9.PubMedCrossRef
65.
Kozma SC, Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays. 2002;24:65–71.PubMedCrossRef
66.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231–41.PubMedCrossRef
67.
Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA. 2001;98:9666–70.PubMedCentralPubMedCrossRef
68.
Lv GF, Dong ML, Hu DH, Zhang WF, Wang YC, Tang CW, Zhu XX. Insulin-mediated inhibition of p38 mitogen-activated protein kinase protects cardiomyocytes in severe burns. J Burn Care Res. 2011;32:591–9.PubMedCrossRef
69.
Kuo WW, Chung LC, Liu CT, Wu SP, Kuo CH, Tsai FJ, Tsai CH, Lu MC, Huang CY, Lee SD. Effects of insulin replacement on cardiac apoptotic and survival pathways in streptozotocin-induced diabetic rats. Cell Biochem Funct. 2009;27:479–87.PubMedCrossRef
70.
Krüger M, Babicz K, von Frieling-Salewsky M, Linke WA. Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy. J Mol Cell Cardiol. 2010;48:910–6.PubMedCrossRef
71.
Morisco C, Marrone C, Trimarco V, Crispo S, Monti MG, Sadoshima J, Trimarco B. Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression. Cardiovasc Res. 2007;76:453–64.PubMedCrossRef
72.
Drenger B, Ostrovsky IA, Barak M, Nechemia-Arbely Y, Ziv E, Axelrod JH. Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinase-mediated inhibition. Anesthesiology. 2011;114:1364–72.PubMedCrossRef
73.
Chiang HT, Cheng WH, Lu PJ, Huang HN, Lo WC, Tseng YC, Wang JL, Hsiao M, Tseng CJ. Neuronal nitric oxide synthase activation is involved in insulin-mediated cardiovascular effects in the nucleus tractus solitarii of rats. Neuroscience. 2009;159:727–34.PubMedCrossRef
74.
Podgorska M, Kocbuch K, Grden M, Szulc A, Szutowicz A, Pawelczyk T. Different signaling pathways utilized by insulin to regulate the expression of ENT2, CNT1, CNT2 nucleoside transporters in rat cardiac fibroblasts. Arch Biochem Biophys. 2007;464(2):344–9.PubMedCrossRef
75.
He Z, Opland DM, Way KJ, Ueki K, Bodyak N, Kang PM, Izumo S, Kulkarni RN, Wang B, Liao R, Kahn CR, King GL. Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia. Arterioscler Thromb Vasc Biol. 2006;26:787–93.PubMedCrossRef
76.
Fullmer TM, Pei S, Zhu Y, Sloan C, Manzanares R, Henrie B, Pires KM, Cox JE, Abel ED, Boudina S. Insulin suppresses ischemic preconditioning-mediated cardioprotection through Akt-dependent mechanisms. J Mol Cell Cardiol. 2013;64:20–9.PubMedCrossRef
77.
Damilano F, Perino A, Hirsch E. PI3K kinase and scaffold functions in heart. Ann N Y Acad Sci. 2010;1188:39–45.PubMedCrossRef
78.
Xu TJ, Liu Y, Yuan B. Effect of insulin in combination with selenium on Irs/PI3K-mediated GLUT4 expression in cardiac muscle of diabetic rats. Eur Rev Med Pharmacol Sci. 2011;15:1452–60.PubMed
79.
Zaha V, Francischetti I, Doenst T. Insulin improves postischemic recovery of function through PI3K in isolated working rat heart. Mol Cell Biochem. 2003;247:229–32.PubMedCrossRef
80.
Chen T, Ding G, Jin Z, Wagner MB, Yuan Z. Insulin ameliorates miR-1-induced injury in H9c2 cells under oxidative stress via Akt activation. Mol Cell Biochem. 2012;369:167–74.PubMedCrossRef
81.
Kemi OJ, Ceci M, Wisloff U, Grimaldi S, Gallo P, Smith GL, Condorelli G, Ellingsen O. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J Cell Physiol. 2008;214:316–21.PubMedCrossRef
82.
Yu W, Chen C, Fu Y, Wang X, Wang W. Insulin signaling: a possible pathogenesis of cardiac hypertrophy. Cardiovasc Ther. 2010;28:101–5.PubMedCrossRef
83.
84.
Zhu Y, Pereira RO, O’Neill BT, Riehle C, Ilkun O, Wende AR, Rawlings TA, Zhang YC, Zhang Q, Klip A, Shiojima I, Walsh K, Abel ED. Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation. Mol Endocrinol. 2013;27:172–84.PubMedCentralPubMedCrossRef
85.
Ginion A, Auquier J, Benton CR, Mouton C, Vanoverschelde JL, Hue L, Horman S, Beauloye C, Bertrand L. Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake. Am J Physiol Heart Circ Physiol. 2011;301:H469–77.PubMedCrossRef
86.
87.
Glynn EL, Lujan HL, Kramer VJ, Drummond MJ, DiCarlo SE, Rasmussen BB. A chronic increase in physical activity inhibits fed-state mTOR/S6K1 signaling and reduces IRS-1 serine phosphorylation in rat skeletal muscle. Appl Physiol Nutr Metab. 2008;33:93–101.PubMedCentralPubMedCrossRef
88.
Mellor KM, Reichelt ME, Delbridge LM. Autophagic predisposition in the insulin resistant diabetic heart. Life Sci. 2013;92:616–20.PubMedCrossRef
89.
90.
Abel ED, O’Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol. 2012;32:2068–76.PubMedCentralPubMedCrossRef
Metadata
Title
The Cardioprotection of the Insulin-Mediated PI3K/Akt/mTOR Signaling Pathway
Authors
Hong Yao
Xiangyang Han
Xiuzhen Han
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 6/2014
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.1007/s40256-014-0089-9

Other articles of this Issue 6/2014

American Journal of Cardiovascular Drugs 6/2014 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees

Adis Drug Evaluation

Icosapent Ethyl: A Review of Its Use in Severe Hypertriglyceridemia

Original Research Article

Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings

Original Research Article

Patterns in the Use of Low-Dose Acetylsalicylic Acid and Other Therapies Following Upper Gastrointestinal Bleeding

Review Article

Thiazide-Like/Calcium Channel Blocker Agents: A Major Combination for Hypertension Management

Adis Drug Evaluation

Epoprostenol (Veletri®, Caripul®): A Review of Its Use in Patients with Pulmonary Arterial Hypertension

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits